Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NanoDoce is a proprietary, submicron particle formulation of docetaxel developed by NanOlogy, LLC. It utilizes the company's Large Surface Area Microparticle (LSAM) technology to create pure drug particles without the need for surfactants or polymers. This formulation is specifically designed for intratumoral injection, which allows for the sustained release of high concentrations of docetaxel directly into the tumor microenvironment while maintaining low systemic exposure and minimizing toxicity. In the context of renal cell carcinoma, NanoDoce is being evaluated as a local treatment for localized T1a tumors, potentially offering a minimally invasive alternative to surgery or thermal ablation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NanoDoce (NanOlogy).